Company: RGNT
Filing Date: 2025-10-24
Form Type: F-1/A
Source: 0001213900-25-101900
Chunk: 272

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-10-24
Form: F-1/A
Chunk 272
---
 case of failure of a funded research and development activity, the Company is not obligated to pay any such royalties        
 to the IIA. As of December 31, 2024, total contingent obligation to IIA is at the amount of $2,665 (including interest at the amount      
 of $321).                                                                                                                                 |

| 2. | In February 2018, the Company entered into a services agreement with Baxter Healthcare Corporation                                     
 (the “Baxter Services Agreement” and “Baxter”, respectively), pursuant to which the Company agreed to purchase                         
 certain services from Teva Medical (Marketing) Ltd. (“Teva”) in connection with GelrinC. In April 2022, we amended the                 
 Baxter Services Agreement to replace Teva as the supplier of Tisseel under the Supply Agreement for GelrinC with Baxter as Teva ceased 
 to distribute Tisseel in Israel.                                                                                                       |

Under the Baxter Services Agreement,
Baxter provides the Company with quality, regulatory and technical support, for up to a maximum aggregate of 40 man-hours per year for
all such support. In consideration for receiving such support, the Company pays Baxter $60 per year until the Company received Food and
Drug Administration (the “FDA”) approval to market GelrinC in the United States. Following FDA approval to market GelrinC
in the United States, the Company will pay Baxter $200 per year during the term of this Services Agreement; however, the year the Company
will receive an FDA approval to market GelrinC in the United States, the Company must pay the remining $140 balance for that year within
30 days after receiving such approval. The Company incurred expenses under the Services Agreement of $60 in each of the year ended December
31, 2024 and 2023.

| 3. | In July 2008, the Company entered into a Supply Agreement with Baxter and Teva which was amended                                    
 and restated on January 6, 2009, pursuant to which the Company agreed to purchase Tisseel VHSD fibrin sealant Kit (the “Tisseel”),  
 from Teva, with Teva being Baxter’s exclusive distribution agent in Israel for Tisseel, for manufacture of GelrinC. The Supply      
 Agreement was amended and restated. The Supply Agreement provides for up to 1,000 kits of Tisseel of the 2 ml Tisseel kit, or 500   
 kits of Tisseel of the 4 ml Tisseel